The US Food and Drug Administration issued a statement saying it has expanded the approved uses of the drug Nexavar (sorafenib) to treat late-stage (metastatic) differentiated thyroid cancer.
Differentiated thyroid cancer
is the most common type of thyroid cancer; the National Cancer Institute's SEER statistics estimate that each year about 60,220 Americans will be diagnosed with thyroid cancer, and 1,850 will die from the disease.
is the most common type of thyroid cancer; the National Cancer Institute's SEER statistics estimate that each year about 60,220 Americans will be diagnosed with thyroid cancer, and 1,850 will die from the disease.Nexavar works by inhibiting multiple proteins in cancer cells, thereby limiting cancer cell growth and division.
The FDA initially approved Nexavar for the treatment of advanced kidney cancer in 2005. Two years later it expanded the drug’s label to treat unresectable liver cancer. Nexavar's new approved use is for patients with locally recurrent or metastatic, progressive differentiated thyroid cancer that no longer responds to radioactive iodine treatment.
that no longer responds to radioactive iodine treatment.Said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research:
Differentiated thyroid cancer can be challenging to treat, especially when unresponsive to conventional therapies. Today’s approval demonstrates the FDA’s commitment to expediting the availability of treatment options for patients
A clinical trial involving 417 participants with locally recurrent or metastatic, progressive differentiated thyroid cancer that did not respond to radioactive iodine treatment established the drug's safety and effectiveness. The findings demonstrated that Nexavar could increase progression free survival (the length of time patients lived without the cancer progressing) by 41 percent. Half of patients receiving Nexavar lived without cancer progression for at least 10.8 months compared to at least 5.8 months for participants receiving a placebo.
Source: FDA
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
No comments:
Post a Comment